Skip to main content
Search form
Search
Subscribe to newsletter +
European Association of Hospital Pharmacists
Menu
Main menu
Home
About Us
Who we are
Board
Staff
Students
Transparency
Contact Information
Call for Expressions of Interest
Members
Associate membership
News
Press Releases
EAHP Newsletters
EAHP in the news
Multimedia Gallery
Events
Calendar
Academy
Synergy Masterclass
EAHP BOOST
Congresses
General Assemblies
Accreditations
EAHP Synergy Certification Courses
Open Learning
Get Involved
Sponsors and partners
HP Practice
EAHP COVID-19 Resource Centre
European Statements of Hospital Pharmacy
What hospital pharmacists do
EAHP-ESCP Oath to Society
FIP global statements
National legislation on hospital pharmacy
Good Practice Initiatives
Common training framework
Environmental Sustainability
European Council for Pharmacy Education Accreditation
Investigation of the hospital pharmacy profession in Europe
Hospital Pharmacy Day
SIGs
Controlled Substances Management
Special Interest Group on Investigation of medication errors and efficiency in oncology
Automated Medication Management
Working Towards Eliminating Avoidable Harm
Hazardous Medicinal Products
Hospital Pharmacist’s Preparedness for in-vivo gene therapy medicinal products
Investigation of Medication Errors in Intensive Care Units
Use of Prefilled Syringes in Intensive Care Units and Operating Theaters
Policy
Resources
Consultations
Position Papers
Get involved and keep up to date
Access to Medicines
Ageing society
Infectious Diseases and AMR
ATMPs
Bar coding medicines to the single unit
Biosimilar medicines
Clinical trials
Digital Health
EMA - EAHP collaboration
European List of Emergency Medicines
Falsified Medicines
Hazardous Medicinal Products
Hospital Pharmacy Specialisation
Medical device regulation
Medicines shortages
Patient safety
Pharmaceuticals in the environment
Pharmacy preparations and compounding
Procurement
Public spending austerity
SmPC
Vaccination
Workforce
Statements
GPIs
Publications
2019 EP Election Manifesto
General information
EAHP Annual report
European Journals of Hospital Pharmacy
EAHP Surveys of HP practice
EAHP History Book
Practical Pharmaceutics
Congress presentation webcasts
2024 European Parliament Election Manifesto
Member Center
You are here
Home
Section 5: Patient Safety and Quality Assurance
5PSQ-032
ADMINISTRATION PROTOCOL FOR PENICILLIN G IN A PATIENT WITH A SEVERE REACTION TO BETALACTAMS AND ABDOMINAL ACTINOMYCOSIS
5PSQ-031
A TWO-YEAR RETROSPECTIVE ANALYSIS OF ADVERSE DRUG REACTIONS WITH FLUOROQUINOLONE AND QUINOLONE ANTIBIOTICS
5PSQ-030
DO WE KNOW WHICH ANTIBIOTICS SHOULD BE AVOIDED IN OUR PATIENTS? ANTIBIOTIC ALLERGY SURVEY AMONG HOSPITALISED PATIENTS
5PSQ-029
EFFECTIVENESS AND SAFETY OF EVOLOCUMAB IN REAL CLINICAL PRACTICE
5PSQ-028
THE GOVERNANCE OF PCSK9-INHIBITORS FOR THE TREATMENT OF PRIMARY HYPERCHOLESTEROLAEMIA: APPROPRIATENESS ANALYSIS
5PSQ-027
EFFECTIVENESS AND SAFETY OF TOLVAPTAN AND UREA FOR THE TREATMENT OF SEVERE SYMPTOMATIC HYPONATRAEMIA: A CASE SERIES
5PSQ-026
IMPACT OF A SAFETY ALERT WITH VALSARTAN IN A HEALTH MANAGEMENT AREA
5PSQ-025
PULMONARY ARTERIAL HYPERTENSION DRUGS: EPIDEMIOLOGICAL ANALYSIS CONCERNING AN ITALIAN DISTRICT
5PSQ-024
MEDICATION ERRORS - A CAUSE FOR MAJOR CARDIOVASCULAR EVENTS IN AN EMERGENCY DEPARTMENT
5PSQ-023
ADEQUATE DIGOXIN DOSAGE IN PATIENTS WITH DIGITALIS TOXICITY
5PSQ-022
AN EVALUATION OF THE PHARMACIST INTERVENTION IN INTRAVENOUS MIXTURES' STABILITY
5PSQ-021
PHARMACOGENETIC TESTING FOR PERSONALISATION OF STATIN THERAPY
5PSQ-020
SAFETY EVALUATION OF INJECTABLE POTASSIUM CHLORIDE PRESCRIPTIONS IN HOSPITAL
5PSQ-019
SWITCHING FROM INDIVIDUALISED NUTRITION TO STANDARDISED OR COMMERCIALISED NUTRITION IN NEWBORNS: ARE THERE ANY POSSIBILITIES?
5PSQ-018
IMPLEMENTATION OF PARENTERAL NUTRITION PRESCRIBING SOFTWARE IN A NEONATAL INTENSIVE CARE UNIT
Pages
« first
‹ previous
…
48
49
50
51
52
53
54
55
56
…
next ›
last »
Follow Us